SCHEMBL3074271

SCHEMBL3074271

Cc1n[nH]c(C)c1-c1ccc(C#N)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.59
AKT2 P31751 2/20 0.59
MKNK1 Q9BUB5 1/20 0.50
FASN P49327 1/20 0.48
DHODH Q02127 1/20 0.46
EP300 Q09472 2/20 0.43
NOTUM Q6P988 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP2A6 P11509 1/20 0.42
SLC11A2 P49281 1/20 0.42
ACVR1 Q04771 1/20 0.41
IKBKB O14920 2/20 0.41
MAP3K14 Q99558 1/20 0.41
CHUK O15111 1/20 0.41
GAA P10253 1/20 0.40
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
KMT2A Q03164 1/20 0.40
OTUD7B Q6GQQ9 1/20 0.39
TNIK Q9UKE5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16209719 0.84 AKT2 (0.79) CHEK1AKT2MKNK1ALDH1A1ACVR1
SCHEMBL24963400 0.83 CHEK1 (0.57) CHEK1AKT2MKNK1FASNACVR1
SCHEMBL30239372 0.83 CHEK1 (0.57) CHEK1AKT2MKNK1FASNACVR1
SCHEMBL27122676 0.79 ERAP1 (0.44) CHEK1AKT2FASNEP300NOTUM
SCHEMBL21262737 0.79 AKT2 (0.70) CHEK1AKT2MKNK1NOTUMALDH1A1
SCHEMBL20448530 0.76 AKT2 (0.66) CHEK1AKT2MKNK1ACVR1IKBKB
SCHEMBL24962586 0.76 IKBKB (0.68) CHEK1AKT2MKNK1NOTUMACVR1
SCHEMBL23091872 0.76 IKBKB (0.68) CHEK1AKT2MKNK1ALDH1A1ACVR1
SCHEMBL25859980 0.76 AKT2 (0.66) CHEK1AKT2MKNK1ALDH1A1ACVR1
SCHEMBL873114 0.75 AKT2 (1.00) CHEK1AKT2MKNK1ACVR1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101842357-A Substituted pyrazole derivatives TAKEDA PHARMACEUTICAL 2010-09-22 CN disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 CHEK1 1685/4885AKT2 1615/4885MKNK1 1473/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 CHEK1 1722/4885AKT2 1611/4885MKNK1 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.